PJ-34 HCl (344458-15-7) is a potent and selective inhibitor of PARP1 and 2. EC50 = 20 nM.1?Reduces ischemia reperfusion injury in a mouse model.2 Displays anti-inflammatory effects in a transient focal cerebral ischemia mouse model.3 PJ-34 HCl causes PARP1 independent, p21 dependent mitotic arrest.4
A poly adenosine diphosphate-ribose polymerase inhibitor, attenuates chromate-induced nephrotoxicity.
east cancer MCF-7.
A poly adenosine diphosphate-ribose polymerase inhibitor, attenuates chromate-induced nephrotoxicity. PJ-34 has a lethal effect on breast cancer cells, both in vitro and in vivo, in particular on breast cancer MCF-7.
PJ-34 hydrochloride hydrate has been used:
- as a poly(ADP-ribose) polymerase (PARP) inhibitor 1 in rats to test the effect of PAPR1 in neuropathic pain
- as a component of protein extraction buffer to enable visualization of the high-molecular-weight smear of PARylated proteins in various cell samples
- as PARP inhibitor in murine MLE-12 epithelial cell line
ChEBI: PJ34 hydrochloride is a hydrochloride salt prepared from equimolar amounts of PJ34 and hydrochloric acid. It has a role as an angiogenesis inhibitor, an anti-inflammatory agent, an antiatherosclerotic agent, an antineoplastic agent, an apoptosis inducer, a cardioprotective agent, an EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor and a neuroprotective agent. It contains a PJ34(1+).
A cell-permeable, water-soluble phenanthridinone-derivative that acts as a potent inhibitor of poly(ADP-ribose) polymerase (PARP; EC
50 = 20 nM). Shown to be about 10,000 times more potent than the prototypical PARP inhibitor, 3-Aminobenzamide (Cat. No.
165350; EC
50 = 200 μM). Does not act as an antioxidant at higher concentrations (1 μM to 10 mM). Exhibits neuroprotection in
in vivo and
in vitro models of stroke. Also available as a 20 mM solution in H
2O(Cat. No.
528151).
Potent inhibitor of poly(ADP-ribose) polymerase (PARP) (EC 50 = 20 nM). ~ 1000-fold more potent than 3-Aminobenzamide . Protects primary neuronal cells from oxygen-glucose deprivation in vitro and reduces infarct size following focal cerebral ischemia in vivo .
1) Pellicciari et al. (2008), On the way to selective PARP-2 inhibitors. Design, synthesis, and preliminary evaluation of a series of isoquinolinone derivatives; Chem. Med. Chem., 3 914
2) Crawford et al. (2010), Postischemic poly (ADP-ribose) polymerase (PARP) inhibition reduces ischemia reperfusion injury in a hind-limb ischemia model; Surgery, 148 110
3) Haddad et al. (2006), Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice; Br. J. Pharmacol., 149 23
4) Madison et al. (2011), The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest; DNA Repair, 10 1003
